Sugi Predict

Sugi Predict / Targets / GCLC

GCLC

Glutamate--cysteine ligase catalytic subunit · P48506 · GCLC on Sugi Atlas →

1,310 patent compounds predicted against GCLC, 842 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL8825844 SCHEMBL8825844 0.54 2/20
SCHEMBL1489334 SCHEMBL1489334 0.53 2/20
SCHEMBL5319953 SCHEMBL5319953 0.53 2/20
SCHEMBL3623288 SCHEMBL3623288 0.53 2/20
SCHEMBL8825872 SCHEMBL8825872 0.53 2/20
Norvaline Norvaline (SCHEMBL4980129) 0.48 2/20
Norvaline Norvaline (SCHEMBL4980131) 0.48 2/20
Lysine Lysine (SCHEMBL2321426) 0.47 2/20
Lysine Lysine (SCHEMBL2326109) 0.47 2/20
SCHEMBL18215380 SCHEMBL18215380 0.47 2/20
SCHEMBL1199780 SCHEMBL1199780 0.47 2/20
SCHEMBL4702263 SCHEMBL4702263 0.47 2/20
SCHEMBL5034721 SCHEMBL5034721 0.47 2/20
SCHEMBL18556768 SCHEMBL18556768 0.47 2/20
SCHEMBL125406 SCHEMBL125406 0.47 2/20
SCHEMBL2050880 SCHEMBL2050880 0.47 2/20
Hydroxyamine Hydroxyamine (SCHEMBL4703121) 0.47 2/20
SCHEMBL20232551 SCHEMBL20232551 0.46 2/20
SCHEMBL5325110 SCHEMBL5325110 0.46 2/20
Hydrochloric Acid Hydrochloric Acid (SCHEMBL1198729) 0.46 2/20

Clinical trials — most relevant to GCLC by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
The Effect of N-Acetyl Cysteine on Cortical Erosion in Early Stage Schizophrenia PHASE4COMPLETED
Effect of N-acetylcysteine on Alcohol and Cocaine Use Disorders: A Double-Blind Randomized Controlled Trial. PHASE4UNKNOWN
Paracetamol Study in Patients With Low Muscle Mass PHASE4UNKNOWN
Cysteine Supplementation in Critically Ill Neonates PHASE2/PHASE3UNKNOWN
The Combined Effect of N-Acetyl Cysteine and Metformin in Polycystic Ovary Syndrome Patients PHASE3RECRUITING
A Study of Oxidative Pathways in MS Fatigue PHASE2COMPLETED
Testing the Combination of MLN4924 (Pevonedistat), Carboplatin, and Paclitaxel in Patients With Advanced Non-small Cell Lung Cancer (NSCLC) Who Have Previously Been Treated With Immunotherapy PHASE2ACTIVE_NOT_RECRUITING
Broccoli Sprout Extracts Trial to See if NRF2 is Enhanced by Sulforaphane Treatment in Patients With COPD PHASE2COMPLETED
Sulfasalazine in Decreasing Opioids Requirements in Breast Cancer Patients PHASE2COMPLETED
Effect of Melatonin in Patients With Diabetic Peripheral Neuropathy PHASE2RECRUITING
Effect of N-acetyl Cysteine and Zinc in Management of Head and Neck Cancer Radiotherapy Induced Oral Mucositis PHASE2COMPLETED
Prevent Cardiac Surgery Associated AKI Trial PHASE2RECRUITING
Sulforaphane in a New Jersey (NJ) Population of Individuals With Autism PHASE2ACTIVE_NOT_RECRUITING
N-Acetylcysteine Protection Against Radiation Induced Cellular Damage PHASE2COMPLETED
A Preliminary Study to Evaluate Cysteamine Therapy in Human Subjects With Non-Alcoholic Steatohepatitis (NASH) PHASE1/PHASE2COMPLETED
the Safety and Efficacy of N-acetyl Cysteine in Children With Drug-Resistant Epilepsy PHASE2COMPLETED
The Effects of a Glutathione Precursor (FT061452),on Serum and Intracellular Glutathione Levels PHASE1COMPLETED
Tolerability of Enteral NAC in Infants PHASE1NOT_YET_RECRUITING
Tolerance and Practicality of Module AOX EARLY_PHASE1COMPLETED
Assessment of the Impact of N-acetylcysteine Supplementation on Physical Performance nanCOMPLETED
Pathogenic Insights and Search for Biomarkers in RFC1-ataxia/CANVAS nanRECRUITING
Treatment Strategy to Enhance Nrf2 Signaling in Older Adults nanCOMPLETED
Effect of Sulfur Amino Acid Depletion and Acetaminophen on Plasma Glutatione nanCOMPLETED
ADAPT: Efficacy of a Dietary Supplement During and After Exercise nanCOMPLETED
Glutathione Levels and Compulsivity nanCOMPLETED
Early Urine Alkalinization and N-Acetylcysteine Administration in the Management of Hair Dye (Paraphenylene Diamine) Intoxication nanCOMPLETED
Thiol/Disulphide Homeostasis in Unexplained Infertility nanCOMPLETED
Cancer and Hearing Loss Related in Children nanCOMPLETED
Supplementation of Oral Reduced Glutathione in Pediatric Cystic Fibrosis Patients nanCOMPLETED
Tecfidera Diffusion Tensor Imaging nanCOMPLETED

Related proteins — ESM-2 sequence neighbours (a GCLC binder may also engage these)

ProteinNameSimilarity
P19468 — 1.000 P19468 →
P97494 — 1.000 P97494 →
Q9NFN6 — 1.000 Q9NFN6 →
Q54PC2 — 0.998 Q54PC2 →
P32477 — 0.995 P32477 →
Q9HF78 — 0.994 Q9HF78 →
Q09768 — 0.993 Q09768 →
Q20117 — 0.992 Q20117 →
Q05029 — 0.990 Q05029 →
C4YLG6 — 0.990 C4YLG6 →
Q5UNW4 — 0.990 Q5UNW4 →
Q6CVT0 — 0.990 Q6CVT0 →
Q03508 — 0.990 Q03508 →
Q9USN5 — 0.990 Q9USN5 →
Q41607 — 0.990 Q41607 →
Q9FY54 — 0.989 Q9FY54 →
Q7N893 — 0.989 Q7N893 →
C7GVL2 — 0.989 C7GVL2 →
Q09298 — 0.989 Q09298 →
Q9W3K5 — 0.989 Q9W3K5 →
Q05318 — 0.989 Q05318 →
P31924 — 0.989 P31924 →
A8ALG9 — 0.988 A8ALG9 →
P14284 — 0.988 P14284 →
Q03460 — 0.988 Q03460 →
Q6CUB5 — 0.988 Q6CUB5 →
Q43845 — 0.988 Q43845 →
P87317 — 0.988 P87317 →
A5K168 — 0.988 A5K168 →
C5M3V9 — 0.988 C5M3V9 →